Cdk4 Inhibitor III (CAS 265312-55-8)
See product citations (1)
QUICK LINKS
Cdk4 Inhibitor III is a small molecule compound that functions as a selective inhibitor of cyclin-dependent kinase 4 (Cdk4). It exerts its mechanism of action by binding to the ATP-binding site of Cdk4, thereby preventing the phosphorylation of the retinoblastoma protein (Rb) and inhibiting the progression of the cell cycle from G1 to S phase. By targeting Cdk4, disrupts the activity of the cyclin D1-Cdk4 complex, which is for the regulation of cell cycle progression. This inhibition ultimately leads to the suppression of cell proliferation and division. In a development setting, Cdk4 Inhibitor III serves for investigating the molecular pathways involved in cell cycle regulation and has the potential to contribute to a deeper understanding of the mechanisms underlying cell proliferation and development.
Cdk4 Inhibitor III (CAS 265312-55-8) References
- A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response. | FitzGerald, J., et al. 2014. PLoS One. 9: e98891. PMID: 24902048
- Small-molecule inhibitors of SETD8 with cellular activity. | Blum, G., et al. 2014. ACS Chem Biol. 9: 2471-8. PMID: 25137013
- Impact of cyclin-dependent kinase CDK4 inhibition on eryptosis. | Lang, E., et al. 2015. Cell Physiol Biochem. 37: 1178-86. PMID: 26418250
- Sensitivity Profiles of Human Prostate Cancer Cell Lines to an 80 Kinase Inhibitor Panel. | Burke, AJ., et al. 2016. Anticancer Res. 36: 633-41. PMID: 26851018
- High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines. | Ghasemi, F., et al. 2018. Oncotarget. 9: 26064-26071. PMID: 29899842
- Identification of ryuvidine as a KDM5A inhibitor. | Mitsui, E., et al. 2019. Sci Rep. 9: 9952. PMID: 31289306
- Isolation and Establishment of a Highly Proliferative, Cancer Stem Cell-Like, and Naturally Immortalized Triple-Negative Breast Cancer Cell Line, KAIMRC2. | Ali, R., et al. 2021. Cells. 10: PMID: 34073849
- Epigenetic regulator UHRF1 orchestrates proinflammatory gene expression in rheumatoid arthritis in a suppressive manner. | Saeki, N., et al. 2022. J Clin Invest. 132: PMID: 35472067
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdk4 Inhibitor III, 10 mg | sc-202988 | 10 mg | $347.00 |